1GDA.F KEMPHARM INC. DL-0001
- Market cap
- EUR 628M
- P/E
- 9.6x
- P/B
- 2.98x
- ROE
- 36.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 1GDA.F undervalued?
Graham number1GDA.F trades 12.6% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
KEMPHARM INC. DL-0001 fundamental analysis
No fundamental analysis for KEMPHARM INC. DL-0001 yet.
KEMPHARM INC. DL-0001 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About KEMPHARM INC. DL-0001
Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 3 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 3 clinical trial to treat narcolepsy. The company is developing Celiprolol,…
Full company profileKEMPHARM INC. DL-0001 financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
KEMPHARM INC. DL-0001 annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 28.7M | 10.2M | 27.5M | 23.6M | 106M | 152M |
| Gross Profit | 26.6M | 9.94M | 25.3M | 16.2M | 90.0M | 145M |
| Operating Income | 7.73M | -24.9M | -49.6M | -87.0M | -4.23M | 49.6M |
| EBITDA | - | -25.5M | -43.5M | -76.4M | 98.7M | 107M |
| Net Income | -8.56M | -26.8M | -46.0M | -106M | 83.2M | 87.8M |
| EPS | -0.24 | -0.78 | -1.11 | -1.97 | 1.46 | 1.48 |
| Balance Sheet | ||||||
| Total Assets | 133M | 115M | 172M | 178M | 285M | 314M |
| Total Liabilities | 5.82M | 40.2M | 110M | 138M | 130M | 74.7M |
| Shareholders' Equity | 127M | 75.1M | 61.9M | 39.7M | 155M | 239M |
| Cash & Short-term Investments | 112M | 65.5M | 43.0M | 33.8M | 62.4M | 122M |
| Cash Flow | ||||||
| Operating Cash Flow | 10.4M | -18.7M | -33.5M | -69.7M | -1.60M | 44.3M |
| Capital Expenditure | 102K | 93.0K | 296K | 0.00 | 835K | 653K |
| Free Cash Flow | 10.3M | -18.8M | -33.8M | -69.7M | -2.43M | 43.6M |
| Ratios | ||||||
| ROE | -6.7% | -35.6% | -74.4% | -266.0% | 53.8% | 36.7% |
| ROA | -6.4% | -23.2% | -26.7% | -59.2% | 29.2% | 28.0% |
| Net Profit Margin | -29.9% | -263.5% | -167.7% | -446.9% | 78.2% | 57.9% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
KEMPHARM INC. DL-0001 dividends
KEMPHARM INC. DL-0001 has not paid dividends in the last 5 fiscal years.
Who owns KEMPHARM INC. DL-0001
- Insiders 1.31%
- Institutions 81.25%
- Public & others 17.45%
- Shares outstanding 59.5M
- Free float 54.0M
KEMPHARM INC. DL-0001 company profile
- Company name
- KEMPHARM INC. DL-0001
- Ticker
- 1GDA.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 61
- Fiscal year end
- December
- Address
- 101 Federal Street, Boston, MA, United States, 02110
- Phone
- 888 958 1253
- Website
- zevra.com
About KEMPHARM INC. DL-0001
Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 3 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 3 clinical trial to treat narcolepsy. The company is developing Celiprolol, an investigational product candidate that is under Phase 3 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit and hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and MIPLYFFA for the treatment of niemann-pick disease type C, an ultra-rare neurodegenerative disease. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. The company was incorporated in 2006 and is headquartered in Boston, Massachusetts.
KEMPHARM INC. DL-0001 management
9- Mr. Neil F. McFarlanePresident, CEO & Director · born 1973
- Mr. Rahsaan W. Thompson J.D.Chief Legal Officer, Secretary & Compliance Officer · born 1971
- Mr. Justin A. Renz CPA, MBACFO & Treasurer · born 1972
- Ms. Nichol L. OchsnerVice President of Investor Relations & Corporate Communications
- Ms. Alison PetersChief People Officer
- Mr. Joshua M. Schafer M.B.A., M.S.Chief Commercial Officer · born 1972
- Dr. Adrian Quartel FFPM, M.D.Consultant · born 1961
- Ms. Tanya HaydenSenior VP & Chief of Staff · born 1980
- Mr. Timothy J. Sangiovanni CPASenior VP of Finance & Corporate Controller · born 1984